ClinicalTrials.gg
Not yet recruitingNCT07576322POLTX_FiberUpdated Nov 16, 2026

Short-Term Safety and Performance of a Wound Dressing Evaluation

An interventional study of Politix Fiber arm in Chronic Wound Care, Local Infection and Safety, sponsored by Sebastian Probst. Not yet recruiting at 3 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Sebastian Probst · Not applicable, Interventional, and Treatment

How we know

Updated Nov 16, 2026Start date movedPrimary completion moved+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

You can paste the following into the **Brief Summary** field: POLTX_CIP_template_e_klinv-mep\_…

The goal of this study is to learn about the safety, wound healing, and ease of use of POLTX_Fiber, an absorbent wound dressing that forms a gel when it takes up wound fluid. The study will include approximately 60 adults receiving outpatient care in Switzerland. Participants will have wounds that have been present for at least four weeks and produce moderate to large amounts of fluid. These may include venous leg ulcers, diabetic foot ulcers, pressure ulcers, or ulcers with more than one cause.

The main questions are:

  • What health problems or dressing-related problems occur during the study?
  • How much does wound size change after 30 days of treatment?
  • Can POLTX_Fiber be removed completely in one piece?
  • How easy is the dressing to apply and remove, and how comfortable is it for patients?

Participants will receive either POLTX_Fiber or Suprasorb Liquacel Pro, another absorbent wound dressing. Dressing assignment will follow a predefined schedule rather than chance. Participants and their care teams will know which dressing is used. Results for each dressing group will be described separately.

Participants will:

  • Receive their assigned dressing for up to 30 days, with dressing changes as needed.
  • Continue usual care for the underlying cause of their wound.
  • Attend wound assessments at the start of treatment, weekly during treatment, and at weeks 8 and 12.
  • Have their wound measured and photographed and checked for signs of infection.
  • Rate pain during dressing changes and report how comfortable the dressing feels.

After the study treatment ends, participants will receive wound dressings prescribed by their care team. Each participant will take part for 12 weeks.

Read the detailed description

This investigator-initiated, multicentre, open-label, non-randomized post-market clinical follow-up study will characterize the short-term safety, clinical performance, and usability of POLTX_Fiber under routine outpatient wound-care conditions. POLTX_Fiber is a CE-marked absorbent gelling fibre dressing used according to the manufacturer's instructions for use.

Consecutive eligible patients will be enrolled at participating centres. Following confirmation of eligibility and written informed consent, participants will be allocated in a 1:1 ratio to POLTX_Fiber or Suprasorb Liquacel Pro using a predefined, non-randomized sequential allocation schedule implemented separately at each site in REDCap. Assignment will not depend on wound characteristics, clinical suitability, or investigator preference. The Suprasorb Liquacel Pro group will provide contextual information on outcomes observed with an established dressing.

Both groups will continue appropriate care for the underlying wound condition. Dressing changes will follow the applicable instructions for use and clinical needs. Changes in treatment or early discontinuation for clinical reasons will be documented, including their rationale.

Wound area will be measured using digital planimetry. Standardized wound photographs will support central review of wound healing, tissue composition, and the condition of the surrounding skin. Although participants and treating clinicians will know the assigned dressing, central wound-image assessors will remain unaware of treatment allocation. Safety surveillance will include adverse events, events considered related to the dressings, and device deficiencies throughout participation.

Analyses will be descriptive and exploratory. Outcomes will be summarized separately for each dressing group using appropriate descriptive statistics. Where informative, confidence intervals will describe the precision of estimates. No formal between-group hypothesis testing is planned, and the study is not designed to establish superiority, non-inferiority, or equivalence between the dressings. Missing data will not be imputed; available observations and missing assessments will be reported.

02

Conditions studied

  • Chronic Wound Care
  • Local Infection
  • Safety

Keywords

  • chronic wound
  • local infection prevention
  • wound exudate
  • safety
03

In context

Lead sponsor

Sebastian Probst is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Diagnosed chronic wound present for at least 4 weeks and no longer than 2 years, showing delayed healing despite standard care. Eligible wound types are venous leg ulcers, diabetic foot ulcers, pressure ulcers, and mixed-etiology ulcers.
  • Moderate to large amounts of wound fluid, assessed using standardized criteria.
  • Wound area between 2 cm² and 50 cm² after appropriate debridement, measured using digital planimetry or standardized wound tracing.
  • Ability and willingness to provide written and comply with study visits and procedures.

Exclusion criteria

Exclusion Criteria:

  • Known allergy or to any component of POLTX_Fiber or Suprasorb Liquacel Pro.
  • Clinically infected wound requiring systemic antibiotic treatment at baseline, according to International Working Group on the Diabetic Foot or European Wound Management Association definitions.
  • Necrotic tissue covering more than 25% of the wound bed or known malignant transformation of the wound.
  • Severe arterial insufficiency, defined as an ankle-brachial index below 0.5.
  • Pregnancy or breastfeeding.
  • Severe systemic illness that may interfere with wound healing or safety assessment, including end-stage renal failure, active cancer under chemotherapy, , or systemic use.
  • Participation in another interventional clinical study or use of an dressing or device within the previous 30 days.
  • Cognitive impairment or psychiatric disorder preventing or compliance with study requirements.
  • Inability to attend scheduled follow-up visits or expected relocation during the 12-week study period.
  • Any condition or circumstance that, in the investigator's opinion, could compromise participant safety or the scientific integrity of the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    POLTX_Fiber arm

    POLTX\_Fiber, an absorbent gelling fiber dressing for moderate-high exudate chronic wounds

    Combination Product: Politix Fiber arm

  • Placebo comparator
    Suprasorb® Liquacel Pro, CE-marked gelling fiber dressing

    Suprasorb® Liquacel Pro arm

    Combination Product: Politix Fiber arm

Interventions

  • Combination productPolitix Fiber arm

    POLTX\_Fiber is a CE-marked absorbent gelling fibre wound dressing. It absorbs wound fluid and forms a gel to maintain a moist wound environment. The dressing will be applied directly to the study wound according to the manufacturer's instructions for use for up to 30 days or until wound closure, whichever occurs first. Dressing changes will depend on wound fluid levels and clinical needs. Participants will continue standard care for the underlying wound condition.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events and device deficiencies

    Number and percentage of participants experiencing adverse events, including serious adverse events and events considered related to the study dressing. Events will be characterized by seriousness, severity, expectedness, relationship to the dressing, action taken, and clinical outcome. Device deficiencies, such as dressing fragmentation or fibres remaining in the wound, will also be recorded and summarized. Results will be reported separately for each dressing group.

    Time frame: 12 Weeks

  2. Percentage wound area reduction from baseline to Day 30

    Percentage change in study wound area, measured using imitoWound digital planimetry. Percentage wound area reduction will be calculated as: \[(baseline wound area - Day 30 wound area) / baseline wound area\] × 100. Positive values indicate a reduction in wound size; negative values indicate an increase. Results will be summarized separately for each dressing group.

    Time frame: Baseline to Day 30 (±1 day).

  3. Proportion of POLTX_Fiber dressing removals completed in one piece

    At each assessed POLTX\_Fiber dressing removal, the clinician will record whether the dressing was completely removed in one piece (yes/no). For each participant receiving POLTX\_Fiber, the number of removals completed in one piece will be divided by the total number of assessed removals and expressed as a percentage. These participant-level percentages will be summarized descriptively. The number of assessed removals and missing assessments will also be reported.

    Time frame: Baseline through Day 30 (±1 day).

Secondary outcomes

  1. Percentage wound area reduction at Weeks 1, 2, 3, 8 and 12

    Percentage wound area reduction from baseline to each specified visit, measured using imitoWound digital planimetry. The percentage will be calculated as: \[(baseline wound area - wound area at the assessment visit) / baseline wound area\] × 100. Positive values indicate a reduction in wound size; negative values indicate an increase. Results will be summarized separately for each dressing group and visit.

    Time frame: 12 weeks

  2. Change in wound tissue composition

    Change from baseline in the percentage of the wound area covered by epithelial tissue, granulation tissue, slough/fibrin, and necrotic tissue, assessed using imitoWound digital wound imaging. Each tissue type will be expressed as a percentage of the total wound area. Changes will be reported in percentage points and summarized separately for each dressing group and visit.

    Time frame: 12 weeks

  3. Change from baseline in the condition of the skin surrounding the wound

    Condition of the skin surrounding the study wound, assessed using standardized digital wound images and documented as healthy, macerated (softened or damaged by excess moisture), or erythematous (red). Changes from the baseline category will be summarized descriptively, with the number and percentage of participants in each category reported separately for each dressing group and visit.

    Time frame: 12 weeks

  4. Local infection signs

    Local infection signs will be assessed using the TILI, recording six indirect criteria and three direct criteria. Change from baseline in the number of indirect criteria present (range: 0-6; higher values indicate more signs of local infection) will be summarized. The number and percentage of participants meeting the TILI criteria for antimicrobial wound treatment-at least five indirect criteria or at least one direct criterion-will also be reported. Results will be summarized separately for each dressing group and visit. TILI supports clinical assessment and does not independently establish a diagnosis of wound infection.

    Time frame: 12 weeks

  5. Investigator assessment of dressing usability and handling

    Usability and handling of POLTX\_Fiber will be assessed using the French version of the Investigator Usability and Handling Questionnaire (IUHQ). Items assess ease of application, comfort during application, ease of removal, and overall satisfaction. Each item uses a five-point scale, with higher ratings indicating a more favourable assessment. Responses will be summarized separately for each item and visit. Dressing integrity upon removal is reported separately as a primary outcome.

    Time frame: Weeks 1, 2, 3 and 4 (end of treatment, Day 30 ±1 day).

  6. Pain intensity before and after dressing changes

    Participants will rate pain intensity immediately before and after dressing changes using a 10-cm visual analogue scale, ranging from 0 (no pain) to 10 (worst pain imaginable). Higher scores indicate greater pain intensity. Scores before and after dressing changes will be summarized separately for each dressing group and visit.

    Time frame: Baseline and Weeks 1, 2, 3 and 4 (end of treatment, Day 30 ±1 day).

  7. Change from baseline in wound exudate amount

    Wound fluid (exudate) amount will be assessed before wound cleansing using the exudate amount item of the Bates-Jensen Wound Assessment Tool. Scores range from 1 (none) to 5 (large), with higher scores indicating more wound fluid. Changes from baseline and the number and percentage of participants in each category will be summarized separately for each dressing group and visit.

    Time frame: 12 weeks

  8. Change from baseline in wound exudate colour

    Wound fluid (exudate) colour will be assessed by the investigator and categorized as serous (clear/amber), serosanguinous (pink), or purulent (opaque/yellow/green). Changes from the baseline category and the number and percentage of participants in each category will be summarized separately for each dressing group and visit.

    Time frame: 12 weeks

  9. Change from baseline in wound exudate odour

    Wound fluid (exudate) odour will be assessed by the investigator and categorized as absent, faint, moderate, or strong. Changes from the baseline category and the number and percentage of participants in each category will be summarized separately for each dressing group and visit.

    Time frame: 12 weeks

  10. Frequency of dressing changes during the treatment period

    The total number of scheduled and unscheduled dressing changes will be recorded for each participant during the treatment period. Participants will be categorized by dressing-change frequency as ≤2, 3-4, or ≥5 changes per week. Total dressing counts and frequency categories will be summarized separately for each dressing group.

    Time frame: Baseline through Day 30 (±1 day).

  11. Patient-reported global tolerability of the dressing

    Participants will independently rate dressing tolerability using a three-point scale: 0 = no issues, 1 = moderate tolerability, and 2 = poor tolerability. Higher scores indicate poorer tolerability. The number and percentage of participants selecting each response will be summarized separately for each dressing group and visit.

    Time frame: Weeks 1, 2, 3 and 4 (end of treatment, Day 30 ±1 day).

07

Study locations

3 sites
  • Hirslanden Clinique des Grangettes
    Chêne-Bougeries, Canton of Geneva 1224, Switzerland
  • Lausanne University Hospital
    Lausanne, Canton of Vaud 1002, Switzerland
  • Instituions Hospital Du Nord Vaudois
    Yverdon-les-Bains, Canton of Vaud 1400, Switzerland
08

References and documents

Individual participant data

Plan to share: Yes — Raw data will be shared using Yareta (https://yareta.unige.ch/home) a Swiss research platform using the FAIR priniples

Supporting information: Analytic code

Time frame: from 2028 until 2029

Access criteria: all researchers

Data sharing details ↗ · yareta.unige.ch

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Oct 2027, 10 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Jun 2026 → Dec 2026, primary completion Jun 2027 → Oct 2027 and completion Sep 2027 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2026
First posted
May 8, 2026
StartEst.
Dec 1, 2026was Jun 2026
Primary completionEst.
Oct 31, 2027was Jun 2027
CompletionEst.
Nov 30, 2027was Sep 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Hirslanden Clinique des Grangettes · Chêne-Bougeries, Switzerland
Show 1 removed
  • Geneva University Hospitals · Geneva, Switzerland
Nov 16, 2026
Start date
Jun 15, 2026→Dec 1, 2026
Nov 16, 2026
Primary completion
Jun 14, 2027→Oct 31, 2027
Nov 16, 2026
Study completion
Sep 30, 2027→Nov 30, 2027
Nov 16, 2026
Eligibility
5 inclusion criteria added, 1 removed; 10 exclusion criteria added, 1 removed
What changed in the criteria
Inclusion criteria
  • RemovedAge ≥ 18 years Chronic wound of 4 weeks to 2 years in duration Moderate to highly exuding wound (clinician-assessed) Wound area 2-50 cm² after debridement Able and willing to provide informed consent and comply with study procedures
  • AddedAge 18 years or older.
  • AddedDiagnosed chronic wound present for at least 4 weeks and no longer than 2 years, showing delayed healing despite standard care. Eligible wound types are venous leg ulcers, diabetic foot ulcers, pressure ulcers, and mixed-etiology ulcers.
  • AddedModerate to large amounts of wound fluid, assessed using standardized criteria.
  • AddedWound area between 2 cm² and 50 cm² after appropriate debridement, measured using digital planimetry or standardized wound tracing.
  • AddedAbility and willingness to provide written informed consent and comply with study visits and procedures.
Exclusion criteria
  • RemovedKnown hypersensitivity to study or comparator dressing components Clinically infected wound requiring systemic antibiotics at baseline Necrotic wound (>25% necrotic tissue) or malignant wound Severe arterial insufficiency (ABI < 0.5) Pregnant or breastfeeding Severe comorbid condition likely to interfere with wound healing or safety evaluation (e.g., end-stage renal disease, active cancer on chemotherapy, immunosuppression) Participation in another interventional study within 30 days Use of investigational wound products within 30 days Cognitive or psychiatric condition limiting consent or compliance Unable to attend follow-up visits or likely to relocate during the study period Any condition that, in the investigator's judgment, may compromise safety or study integrity
  • AddedKnown allergy or hypersensitivity to any component of POLTX_Fiber or Suprasorb Liquacel Pro.
  • AddedClinically infected wound requiring systemic antibiotic treatment at baseline, according to International Working Group on the Diabetic Foot or European Wound Management Association definitions.
  • AddedNecrotic tissue covering more than 25% of the wound bed or known malignant transformation of the wound.
  • AddedSevere arterial insufficiency, defined as an ankle-brachial index below 0.5.
  • AddedPregnancy or breastfeeding.
  • AddedSevere systemic illness that may interfere with wound healing or safety assessment, including end-stage renal failure, active cancer under chemotherapy, immunosuppression, or systemic corticosteroid use.
  • AddedParticipation in another interventional clinical study or use of an investigational dressing or device within the previous 30 days.
  • AddedCognitive impairment or psychiatric disorder preventing informed consent or compliance with study requirements.
  • AddedInability to attend scheduled follow-up visits or expected relocation during the 12-week study period.
  • AddedAny condition or circumstance that, in the investigator's opinion, could compromise participant safety or the scientific integrity of the study.
Nov 16, 2026
Primary outcomes
3 added, 2 removed
What changed in the outcomes
  • AddedIncidence of adverse events and device deficienciesTime frame: 12 Weeks
  • AddedPercentage wound area reduction from baseline to Day 30Time frame: Baseline to Day 30 (±1 day).
  • AddedProportion of POLTX_Fiber dressing removals completed in one pieceTime frame: Baseline through Day 30 (±1 day).
  • RemovedPhotographic evaluationTime frame: 12 Weeks
  • RemovedChange in wound areaTime frame: 12 weeks
Nov 16, 2026
Secondary outcomes
2 edited, 8 added, 9 removed, 1 description edited
What changed in the outcomes
  • EditedLocal Infection Assessmentinfection signsTime frame: 12 weeks
  • EditedFrequency of dressing changes during the treatment periodTime frame: 12 weeks → Baseline through Day 30 (±1 day).
  • AddedPercentage wound area reduction at Weeks 1, 2, 3, 8 and 12Time frame: 12 weeks
  • AddedChange from baseline in the condition of the skin surrounding the woundTime frame: 12 weeks
  • AddedInvestigator assessment of dressing usability and handlingTime frame: Weeks 1, 2, 3 and 4 (end of treatment, Day 30 ±1 day).
  • AddedPain intensity before and after dressing changesTime frame: Baseline and Weeks 1, 2, 3 and 4 (end of treatment, Day 30 ±1 day).
  • AddedChange from baseline in wound exudate amountTime frame: 12 weeks
  • AddedChange from baseline in wound exudate colourTime frame: 12 weeks
  • AddedChange from baseline in wound exudate odourTime frame: 12 weeks
  • AddedPatient-reported global tolerability of the dressingTime frame: Weeks 1, 2, 3 and 4 (end of treatment, Day 30 ±1 day).
  • RemovedWound healing progressionTime frame: 12 weeks
  • RemovedGlobal Tolerability AssessmentTime frame: 12 weeks
  • RemovedPain (Visual Analogue Scale (VAS)Time frame: 12 weeks
  • RemovedExudate managementTime frame: 12 weeks
  • RemovedGlobal Tolerability Assessment by participantsTime frame: 12 weeks
  • DescriptionChange in wound tissue composition: how it is measured was reworded
  • Removedother outcomeSociodemographic and diagnostic dataTime frame: Baseline
  • Removedother outcomeWound etiologyTime frame: Baseline
  • Removedother outcomeWound anatonical locationTime frame: Baseline
  • Removedother outcomeWound diagnostic classificationTime frame: Baseline
Nov 16, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Lausanne University Hospital · Lausanne, SwitzerlandContact •••1111→•••0583
  • Instituions Hospital Du Nord Vaudois · Yverdon-les-Bains, SwitzerlandContact •••4444→•••4199
Nov 16, 2026
Title
Short-Term Safety and Performance of Twoa Wound DressingsDressing Evaluation
Nov 16, 2026
Sponsor
Collaborators added: Hirslanden Clinic des Grangettes; collaborators removed: University Hospital, Geneva
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    1 site added, 1 site removed
    Show site
    • Hirslanden Clinique des Grangettes · Chêne-Bougeries, Switzerland
    Show 1 removed
    • Geneva University Hospitals · Geneva, Switzerland
    Start date Jun 15, 2026→Dec 1, 2026
    Primary completion Jun 14, 2027→Oct 31, 2027
    Study completion Sep 30, 2027→Nov 30, 2027
    Eligibility 5 inclusion criteria added, 1 removed; 10 exclusion criteria added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedAge ≥ 18 years Chronic wound of 4 weeks to 2 years in duration Moderate to highly exuding wound (clinician-assessed) Wound area 2-50 cm² after debridement Able and willing to provide informed consent and comply with study procedures
    • AddedAge 18 years or older.
    • AddedDiagnosed chronic wound present for at least 4 weeks and no longer than 2 years, showing delayed healing despite standard care. Eligible wound types are venous leg ulcers, diabetic foot ulcers, pressure ulcers, and mixed-etiology ulcers.
    • AddedModerate to large amounts of wound fluid, assessed using standardized criteria.
    • AddedWound area between 2 cm² and 50 cm² after appropriate debridement, measured using digital planimetry or standardized wound tracing.
    • AddedAbility and willingness to provide written informed consent and comply with study visits and procedures.
    Exclusion criteria
    • RemovedKnown hypersensitivity to study or comparator dressing components Clinically infected wound requiring systemic antibiotics at baseline Necrotic wound (>25% necrotic tissue) or malignant wound Severe arterial insufficiency (ABI < 0.5) Pregnant or breastfeeding Severe comorbid condition likely to interfere with wound healing or safety evaluation (e.g., end-stage renal disease, active cancer on chemotherapy, immunosuppression) Participation in another interventional study within 30 days Use of investigational wound products within 30 days Cognitive or psychiatric condition limiting consent or compliance Unable to attend follow-up visits or likely to relocate during the study period Any condition that, in the investigator's judgment, may compromise safety or study integrity
    • AddedKnown allergy or hypersensitivity to any component of POLTX_Fiber or Suprasorb Liquacel Pro.
    • AddedClinically infected wound requiring systemic antibiotic treatment at baseline, according to International Working Group on the Diabetic Foot or European Wound Management Association definitions.
    • AddedNecrotic tissue covering more than 25% of the wound bed or known malignant transformation of the wound.
    • AddedSevere arterial insufficiency, defined as an ankle-brachial index below 0.5.
    • AddedPregnancy or breastfeeding.
    • AddedSevere systemic illness that may interfere with wound healing or safety assessment, including end-stage renal failure, active cancer under chemotherapy, immunosuppression, or systemic corticosteroid use.
    • AddedParticipation in another interventional clinical study or use of an investigational dressing or device within the previous 30 days.
    • AddedCognitive impairment or psychiatric disorder preventing informed consent or compliance with study requirements.
    • AddedInability to attend scheduled follow-up visits or expected relocation during the 12-week study period.
    • AddedAny condition or circumstance that, in the investigator's opinion, could compromise participant safety or the scientific integrity of the study.
    Primary outcomes 3 added, 2 removed
    What changed in the outcomes
    • AddedIncidence of adverse events and device deficienciesTime frame: 12 Weeks
    • AddedPercentage wound area reduction from baseline to Day 30Time frame: Baseline to Day 30 (±1 day).
    • AddedProportion of POLTX_Fiber dressing removals completed in one pieceTime frame: Baseline through Day 30 (±1 day).
    • RemovedPhotographic evaluationTime frame: 12 Weeks
    • RemovedChange in wound areaTime frame: 12 weeks
    Secondary outcomes 2 edited, 8 added, 9 removed, 1 description edited
    What changed in the outcomes
    • EditedLocal Infection Assessmentinfection signsTime frame: 12 weeks
    • EditedFrequency of dressing changes during the treatment periodTime frame: 12 weeks → Baseline through Day 30 (±1 day).
    • AddedPercentage wound area reduction at Weeks 1, 2, 3, 8 and 12Time frame: 12 weeks
    • AddedChange from baseline in the condition of the skin surrounding the woundTime frame: 12 weeks
    • AddedInvestigator assessment of dressing usability and handlingTime frame: Weeks 1, 2, 3 and 4 (end of treatment, Day 30 ±1 day).
    • AddedPain intensity before and after dressing changesTime frame: Baseline and Weeks 1, 2, 3 and 4 (end of treatment, Day 30 ±1 day).
    • AddedChange from baseline in wound exudate amountTime frame: 12 weeks
    • AddedChange from baseline in wound exudate colourTime frame: 12 weeks
    • AddedChange from baseline in wound exudate odourTime frame: 12 weeks
    • AddedPatient-reported global tolerability of the dressingTime frame: Weeks 1, 2, 3 and 4 (end of treatment, Day 30 ±1 day).
    • RemovedWound healing progressionTime frame: 12 weeks
    • RemovedGlobal Tolerability AssessmentTime frame: 12 weeks
    • RemovedPain (Visual Analogue Scale (VAS)Time frame: 12 weeks
    • RemovedExudate managementTime frame: 12 weeks
    • RemovedGlobal Tolerability Assessment by participantsTime frame: 12 weeks
    • DescriptionChange in wound tissue composition: how it is measured was reworded
    • Removedother outcomeSociodemographic and diagnostic dataTime frame: Baseline
    • Removedother outcomeWound etiologyTime frame: Baseline
    • Removedother outcomeWound anatonical locationTime frame: Baseline
    • Removedother outcomeWound diagnostic classificationTime frame: Baseline
    Sponsor Collaborators added: Hirslanden Clinic des Grangettes; collaborators removed: University Hospital, Geneva
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Lausanne University Hospital · Lausanne, SwitzerlandContact •••1111→•••0583
    • Instituions Hospital Du Nord Vaudois · Yverdon-les-Bains, SwitzerlandContact •••4444→•••4199
    Title Short-Term Safety and Performance of Twoa Wound DressingsDressing Evaluation
    + 4 other changes: verification date, description, design details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07576322
Lead sponsor
Sebastian Probst
Collaborators
eHnv Hospital, CHUV, Lausanne University Hospitals, Switzerland, Hirslanden Clinic des Grangettes
Responsible party
Sebastian Probst (Professor of Tissue Viability and Wound Care, School of Health Sciences Geneva) — Sponsor-investigator
First posted
May 8, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Oct 31, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Sebastian Probst, Prof. Dr.
Contact
sebastian.probst@hesge.ch
41 22-558-6563
André Frei, MSc
Contact
andre.frei@hesge.ch
41 22-558-6050

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Sebastian Probst

Start the discussion